Navilyst Medical

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Navilyst Medical
Private
Industry Medical devices
Founded 2008
Headquarters Marlborough, Massachusetts
Key people
Joseph M. DeVivo, CEO
Products PASV Valve Technology, Xcela PICCs and Ports, Vaxcel PICCs and Ports, Xcela PICC with PASV Valve Technology, NAMIC Fluid Management products and Exodus Drainage Catheters.
Owner Avista Capital Partners
Parent AngioDynamics, Inc.
Website www.navilystmedical.com

Navilyst Medical, Inc. is a manufacturer of vascular medical equipment, including catheters, ports, and embolization devices. The company name is based on the root navi (as in "navigation") and the suffix lyst (as in "catalyst").[1]

History[edit]

Navilyst Medical was founded in February 2008 out of the $425 million Avista Capital Partners acquisition of Boston Scientific's Fluid Management and Vascular Access division. The acquisition was seen as a way to focus on "opportunities it sees with vein-access devices, instead of competing for resources with many other projects inside the larger company [of Boston Scientific]," primarily within the hospital realm.[1][2] The purchase included Boston Scientific's manufacturing plant for NAMIC angiography and angioplasty fluid management devices in Glens Falls, NY.[3][4]

In January 2012, news broke that vascular device manufacturer AngioDynamics, Inc. would be purchasing Navilyst for $372 million, calling the opportunity "an excellent platform for future revenue and earnings growth, as well as substantial cash flow generation."[5] The purchase was completed on May 22, 2012, valued at $355 million.[6] Navilyst Medical was allowed to continue as a subsidiary/division of AngioDynamics.

Changes arrived at the Glens Falls plant in December 2013 with the announcement of consolidation efforts with AngioDynamics' other facility in Queensbury. The company estimated 80 to 100 jobs would be shed over a period of three years, with the Queensbury plant being converted into a distribution center.[7] A year later, the Glens Falls plant was hit with a warning letter from the FDA concerning faults with design control and real-time aging testing found during on-site inspections, though the company strove "to rectify the deficiencies promptly."[8][9]

References[edit]

  1. ^ a b Timmerman, L. (8 August 2008). "Navilyst Medical, Boston Scientific Spin-Off, Aiming to Tap Veins Without Causing Infections". EXOME. Xconomy, Inc. Retrieved 29 February 2016. 
  2. ^ "Navilyst Medical Announces Global Debut Today: Former Boston Scientific Business Units Combine to Lead Fluid Management and Vascular Access Markets". PRWeb. Vocus PRW Holdings, LLC. 4 August 2008. Retrieved 29 February 2016. 
  3. ^ "Medical device maker gets new name". The Post-Star. Lee Enterprises, Inc. 4 August 2008. Retrieved 29 February 2016. 
  4. ^ Hollmer, M. (1 September 2008). "Newly hatched life science company eyes expansion". Boston Business Journal. American City Business Journals. Retrieved 29 February 2016. 
  5. ^ Mukherjee, S.; Kaushik, K. (31 January 2012). "AngioDynamics to buy Navilyst Medical for $372 million". Reuters. Thomson Reuters. Retrieved 29 February 2016. 
  6. ^ "AngioDynamics Completes Acquisition of Navilyst Medical". AngioDynamics, Inc. 22 May 2012. Retrieved 29 February 2016. 
  7. ^ Donnelly, S. (5 December 2013). "AngioDynamics announces plan to consolidate local facilities, cut jobs". The Post-Star. Lee Enterprises, Inc. Retrieved 29 February 2016. 
  8. ^ House, D.W. (14 November 2014). "AngioDynamics gets Warning Letter". Seeking Alpha. Retrieved 29 February 2016. 
  9. ^ "Commission File Number 000-50761". U.S. Securities and Exchange Commission. 5 November 2014. Retrieved 29 February 2016.